key: cord-0798951-g9gnlnuq authors: Mohamed, Kawthar; Rzymski, Piotr; Islam, Md Shahidul; Makuku, Rangarirai; Mushtaq, Ayesha; Khan, Amjad; Ivanovska, Mariya; Makka, Sara A.; Hashem, Fareeda; Marquez, Leander; Cseprekal, Orsolya; Filgueiras, Igor Salerno; Fonseca, Dennyson Leandro M.; Mickael, Essouma; Ling, Irene; Arero, Amanuel Godana; Cuschieri, Sarah; Minakova, Kseniia; Rodríguez‐Román, Eduardo; Abarikwu, Sunny O.; Faten, Attig‐Bahar; Grancini, Giulia; Cabral‐Marques, Otavio; Rezaei, Nima title: COVID‐19 vaccinations: The unknowns, challenges, and hopes date: 2021-12-10 journal: J Med Virol DOI: 10.1002/jmv.27487 sha: c36ed165b3865cc0f25cb87345b112e76c19b7cf doc_id: 798951 cord_uid: g9gnlnuq The entire world has been suffering from the coronavirus disease 2019 (COVID‐19) pandemic since March 11, 2020. More than a year later, the COVID‐19 vaccination brought hope to control this viral pandemic. Here, we review the unknowns of the COVID‐19 vaccination, such as its longevity, asymptomatic spread, long‐term side effects, and its efficacy on immunocompromised patients. In addition, we discuss challenges associated with the COVID‐19 vaccination, such as the global access and distribution of vaccine doses, adherence to hygiene guidelines after vaccination, the emergence of novel severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants, and vaccine resistance. Despite all these challenges and the fact that the end of the COVID‐19 pandemic is still unclear, vaccines have brought great hope for the world, with several reports indicating a significant decline in the risk of COVID19‐related infection and hospitalizations. COVID-19 has impacted the entire world, which is feeling the full brunt of the current pandemic. It is negatively affecting the international economy from the primary sectors such as agriculture, and petroleum, and oil to the secondary sectors, including the manufacturing industry and the tertiary sectors like education and finance industry. 3 For instance, the social consequences of the pandemic have increased domestic violence, including emotional, physical, and sexual abuse, prejudice toward individuals of Asian descent, adverse changes to dietary habits, as well as substance use and abuse since the beginning of the pandemic. [3] [4] [5] [6] Furthermore, the COVID19 pandemic has also caused psychological and physical burnout of healthcare personnel. Significant changes have also been made in the healthcare facilities to attend to the substantial number of infected patients. 7, 8 It is worth mentioning, most countries have taken hygiene guidelines and travel restrictions as their primary strategy in curbing this pandemic; however, the effectiveness of this strategy depends on the governments' strictness of these rules and measures and the general public's adherence to them. 9, 10 Consequently, the remaining potential player against this dilemma is herd immunity, defined as having 50%-85% of the population immunized either by being naturally infected with COVID-19 or by vaccination. By November 2021, over twenty vaccines were approved in different parts of the world, including adenoviral vector vaccines, mRNA vaccines, subunit vaccines, vaccines based on inactivated SARS-CoV-2, and a DNA vaccine. Vaccination serves as a two-edged sword as it is the best tool for curbing this pandemic and bringing ambiguity, uncertainty, and MOHAMED ET AL. | 1337 challenges that the world might face during its providence or later unknown long effects. For instance, the data delivered from vaccine clinical trials on safety profile, immunogenicity, and efficacy in preventing symptomatic infection are limited to the context of these trials and not for their massive use. 11, 12 This review aims to revisit the unknowns, challenges, and hopes of the COVID-19 vaccination program and potential measures to overcome them. Cases of COVID-19 were first reported in late December 2019 in the city of Wuhan in China's Hubei province. 13 and (f) manufacturing postmarketing surveillance. 16 In addition, other vaccines are widely used, but they merely have national approval, like Sputnik V (Gamaleya Research Institute), NVX-CoV2373 (Novavax), and Covaxin (Bharat Biotech). 15 For more information on vaccines with either national or EUL approval ( Table 1) . All the above-mentioned COVID-19 vaccines use the viral spike protein as their targeted antigen except for the inactivated vaccines group, which targets the virus as a whole. Likewise, all vaccines induce both cellular and humoral responses with the exception of inactivated vaccines. 16 3 | THE UNKNOWNS Vaccines are developed to train the immune system for providing immunity against infections. Many vaccines are primarily targeted to prevent disease and may not necessarily protect against specific infections. 21 Even those that provide "sterilizing immunity" may wane in the long run. However, protection against disease or disease progression (severity) may persist due to immune memory. 22 The protective immunity through humoral and cellular response against SARS-CoV-2 in humans in natural and experimental settings has not been fully understood since most studies were performed in animal models. 23 However, selected leading vaccines have demonstrated encouraging efficacy rates. Data suggests that about 95% of subjects retain substantial immune memory fairly stable up to 8 months of natural infection provided by antigen-specific antibodies, memory B cells, and T cells then decline modestly. 24 Regardless of type, it takes time to develop effective immunity after vaccination. Experts say, even a single dose of any vaccine can provide protection eventually. 25 For example, a study found that the AZD1222 vaccine can provide 76% protection up to 12 weeks after a single dose and subsequently decline the transmission rate by 67%. 26 A recent study revealed that vaccines should have at least 70% efficacy to halt an epidemic and for an ongoing epidemic, 80% efficacy is needed without any other measures when vaccination covers at least 75% of the population. 27 Therefore, preventive measures (social distancing, personal hygiene, handwashing, etc.) and adopting a policy to ensure vaccination coverage would undoubtedly challenge the pandemic in time. More across the border, vaccine trials should be performed to assure the longevity of various vaccines. The median incubation period for COVID-19 is approximately five days, and those who develop symptoms will do so within 11.5 days. One of the most worrying aspects of this pandemic is the substantial number of undocumented infections (asymptomatic individuals) that facilitate the rapid spread of SARS-CoV-2. This imposes a significant public health issue even though it is expected for any pandemic to show a higher frequency of asymptomatic infections. 28 these individuals can still contribute to the recurrence and disease spread. 29 They might have the same viral load as symptomatic subjects. 29 Vaccination is well-known to play an essential role in controlling the spread of infectious diseases. However, the COVID19 is yet unlikely to end, although vaccine programs have advanced in numerous countries. We are currently facing the challenge of scaling up production to attend to the global demand for vaccination doses. A global strategy is still missing to ensure faster affordability and sustainable financing of COVID-19 vaccines in developing countries that might lack the resources to buy the required quantities of vaccines. Thus, still with a high level of asymptomatic and unvaccinated subjects circulating worldwide, this can pose a challenge to the efficacy of the vaccination in controlling the COVID19 pandemic. In addition, several questions remain to be answered on several levels, such as accurate reinfection risk before or after the second dosage, reinfection possibility regardless of onset yet asymptomatically, and reinfection possibility with the chance to transmit disease to others. 29 and shedding starting in the upper respiratory airways. Therefore, all of its replication and infectivity stages should be targeted via vaccination to control its infectivity and spread. Despite these challenges, the current COVID-19 vaccines have been shown to limit viremia and COVID-19 related syndromes via IgG response induction. However, they lack local mucosal IgA response, which is mainly responsible for the disease transmissibility. 30 Hence, until more knowledge is gathered on the mucosal immunity following systemic vaccination, the virus transmission among asymptomatic vaccinated individuals through droplets cannot be excluded. Thus, still demanding the precaution measures started since the beginning of the pandemic. In December 2020, the clinical trial with the BNT162b2 vaccine showed 95% protection against infection, and safety was surveilled over two months with similar results to other viral vaccines. 31 This first trial was followed by several studies evaluating the efficacy and safety of other candidate vaccines against COVID19, which adopted SARS-CoV-2 confirmed symptomatic cases as their primary efficacy endpoint. 32 However, these studies did not evaluate asymptomatic individuals, 32 posing a great hurdle to scientifically answer whether vaccinated asymptomatic individuals transmit the disease or not. In this context, although significantly lower viral load following the inoculation of mRNA vaccines indicates that vaccination also leads to lower viral transmissibility. However, studies are needed to address this issue. Another critical question that remains unanswered is whether vaccination will limit reinfection by SARS-CoV-2 with the same or new variants that have recently emerged. [33] [34] [35] In addition, future studies need to be performed to determine if the administration of a seasonal vaccine against COVID19 will be required to avoid the outbreak of a new pandemic. Overall, it is safe to say that vaccines can limit the intensity of the disease for those who would be severely infected to mild infection or perhaps asymptomatic and possibly reduce viral load in asymptomatic individuals to decrease infectiousness. This will contribute to lowering the pandemic spread but not totally eradicating it as it was learned from previous pandemics. 3.3 | Long-term side effects of COVID-19 vaccination severity, the dynamics, and the persistence of seroconversion after infection might differ. In addition, this group is often characterized by significantly higher mortality rates. 43, 44 According to the meta-analysis of Gresham et al., 45 Although these efforts significantly contributed to building a fair vaccination distribution plan, 54 The minimum time needed to induce an optimal level of immunity was observed in vaccines produced by Pfizer-BioNTech and Novavax companies seven days after the seconnd dose, aka 28 days from the first dose. 31, 57 Ad26.COV2.S and Ad5-nCoV vaccines mediated immunity after 28 days but with a single dose. 55, 56 Nevertheless, the maximum time needed for the induction of immunity was 42 days 58,59 (Table 2) . It is worth mentioning, due to the emergence of new COVID-19 variants or the asymptomatic spread, 67 Thus, a sandwich strategy of hygiene guidelines and vaccination may contribute to better limiting SARS-CoV-2 spread. The coronaviruses belong to RNA viruses that present a high mutation rate, typically exceeding DNA viruses. 69 dose, the efficacy against hospitalization remains very high during the 6 months at the level of 93%. 89 As long as the serum levels of neutralization antibodies decrease within a few months following the completion of the initial vaccination regime (Figure 2) , the protection against severe COVID-19 remains high due to adaptive cellular immune response that is retained and is recognizing B. antibodies, 83 or/and as a consequence of random mutations due to a large number of infections in the population. In this context, it seems reasonable to prioritize immunosuppressed individuals' vaccination to lower the risk of virus evolution due to its prolonged host persistence. 100, 101 Furthermore, because prolonged viral shedding was also observed in children, including asymptomatic cases, it cannot be excluded that they also may be a good host for novel mutations to emerge. Currently, no vaccine has been authorized for administration to children and adolescents, although the first clinical trials targeting these groups were initiated (e.g., NCT04796896 and NCT04800133). Vaccine chances of resistance are low, and they are attributed to the absence of one of three essential features that vaccines possess, that is, the vaccine needs to target multiple virus epitopes simultaneously, inducing a redundant and evolutionarily robust immune response; it must suppress pathogen growth and eliminate transmission, and it should provide protection against all circulating serotypes of a given pathogen. 112 Thus, considering the current COVID19 pandemic context that we reviewed here, it will be necessary to develop long-term studies that monitor the evolution of the immune protection induced by COVID19 vaccines. 113 The combination of vaccine and drug development against COVID19 must be continued. 111 The COVID-19 pandemic that has caught the world unawares has raised various issues regarding pandemic and vaccination ethics. These concerns cover a wide range of topics, such as testing and trial, distribution, prioritization, beneficence and maleficence, cultural and religious differences, politics and diplomacy, surveillance, and life and death, among others. In addition, the prevalence of misinformation and the promotion of "alternative" cures or remedies do nothing to win the fight against anti-vaxxers. As a modified iteration of the classic Trolley Problemone that fits the existing COVID-19 vaccination predicamentone can look at the ethical dilemma as such: F I G U R E 2 An example of dynamics of serum neutralizing IgG anti-S1-RBD antibodies levels induced by administration of BNT162b2 vaccine in 36-years old male with no immune deficiency. Note the decreasing levels over the course of 8 months after a second dose and a significant rise (above the upper limit of detection in the assay) after a third (booster) dose Putting this thought experiment in the context of the real world makes the problem more complicated because then, one would be presented with more choices. In many instances, some of these choices would seem to be better choices than others. Some would say that the benefits of the vaccine outweigh the risks and that the disadvantaged must be prioritized above everyone else. 115 Others would raise questions on the power of the State to legally compel its citizens to be vaccinated or to decide to donate a portion of Stateacquired vaccines to poorer countries despite the fact that some of its own citizens have yet to be vaccinated. 116 There are also those who would consider the political and diplomatic implications of exploiting the pandemic and the vaccine race to secure a better position on the world stage. 117 These are just some of the ethical challenges that confront the ongoing vaccination efforts. Although the road to ending the COVID-19 pandemic is still uncertain, vaccines have brought the world hope, with studies pointing towards a significant decline in the risk of COVID19related infection and hospitalizations. However, there is evidence that the efficacy of vaccines against infection decrease in time. Eradication of SARS-CoV-2 is unlikely; therefore, one should note that emphasis must be placed on decreasing COVID-19 severity and deaths, while prevention of infection should be seen as a secondary goal and may also require development and implementation of vaccines based on novel approaches or optimization of vaccines for novel SARS-CoV-2 variants. Nevertheless, the evolution of SARS-CoV-2 must remain monitored globally. Of note, the pandemic has invoked international goal-oriented collaborations. Exceptional efforts by scientists, with years of advanced research, along with the enormous funding and the faltering global economy 118 are some factors that have led to the emergence of hundreds of projects within a year. 119 These projects bear scope for improvement in terms of potency, safety, and effectiveness of novel vaccines, and possibly, development of vaccines better-suited for distinct population groups and variations in the viral genome as well. 120 However, understanding vaccine-hesitancy is imperative for achieving desired levels of immunization. Addressing the scientific, medical, and ethical challenges that follow vaccine development (inequity, recipient prioritization, etc.) may enable better implementation. Thus, vaccination can control the spread of the COVID-19 infection, in parallel to the multiple epidemiologic factors, and the several social measurements applied during this pandemic. We acknowledge the São Paulo Research Foundation (FAPESP grants 2018/18886-9, 2020/01688-0, and 2020/07069-0 to OCM) for financial support. Borderless collaboration is needed for COVID-19: a disease that knows no borders The socio-economic implications of the coronavirus pandemic (COVID-19): a review Substance use and abuse, COVID-19-related distress, and disregard for social distancing: a network analysis Dietary choices and habits during COVID-19 lockdown: experience from Poland COVID-19-related prejudice toward Asian medical students: a consequence of SARS-CoV-2 fears in Poland International efforts to save healthcare personnel during COVID-19 COVID-19 affects healthy pediatricians more than pediatric patients Health care policies and COVID-19 prevalence: is there any association? Adherence of the general public to self-protection guidelines during the COVID-19 pandemic Immunological considerations for COVID-19 vaccine strategies What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster COVID-19 vaccine: A recent update in pipeline vaccines, their design and development strategies WHO news updates A review of the progress and challenges of developing a vaccine for COVID-19 FDA takes key action in fight against COVID-19 by issuing emergency use authorization for first COVID-19 vaccine An mRNA Vaccine against SARS-CoV-2 -preliminary report Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial WHO vaccination greatly reduces disease, disability, death and inequity worldwide Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection How effective is a single vaccine dose against Covid-19? Accessed Pfizer vaccine: Single dose '90 per cent effective after 21 days Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention Asymptomatic coronavirus infection: MERS-CoV and SARS-CoV-2 (COVID-19) COVID-19 transmission through asymptomatic carriers is a challenge to containment. VInfluenza Other Respir Viruses COVID-19 vaccines may not prevent nasal SARS-CoV-2 infection and asymptomatic transmission Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine Evaluating the Efficacy of COVID-19 vaccines What reinfections mean for COVID-19 Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks Understanding drivers of COVID-19 vaccine hesitancy among Blacks A side effect resource to capture phenotypic effects of drugs | Molecular Systems Biology Information for UK recipients on COVID 19 Vaccine AstraZeneca COVID-19 Vaccine EUA Fact Sheet for Recipients and Caregivers Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases Covid-19 vaccine and autoimmunity: awakening the sleeping dragon Thrombotic thrombocytopenia associated with COVID-19 infection or vaccination: Possible paths to platelet factor 4 autoimmunity Patterns of seroconversion for SARS-CoV-2 IgG in patients with malignant disease and association with anticancer therapy Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients More than 1.04 billion shots given: Covid-19 Tracker Coronavirus Pandemic (COVID-19). Our World in Data A global database of COVID-19 vaccinations Vaccine nationalism' threatens global plan to distribute COVID-19 shots fairly Fair allocation mechanism for COVID-19 vaccines through the COVAX Facility World Health Organization. WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination Despite obstacles, WHO unveils plan to distribute vaccine Our World in Data COVID-19 vaccine boosters: the good, the bad, and the ugly Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK phase 3 trial Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Bharat biotech-vaccines & bio-therapeutics manufacturer in India Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates Coronavirus Vaccine Tracker. The New York Times Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebocontrolled, phase 1/2 clinical trial Impact of the COVID-19 vaccine on asymptomatic infection among patients undergoing pre-procedural COVID-19 molecular screening Vaccine breakthrough infections with SARS-CoV-2 variants Complexities of viral mutation rates Influenza A virus polymerase: structural insights into replication and host adaptation mechanisms Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity Evolution of the COVID-19 vaccine development landscape Human SARS CoV-2 spike protein mutations Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness Safety and Immunogenicity of two RNA-based Covid-19 vaccine candidates Investigation of novel SARS-COV-2 variant: variant of Concern 202012/01 (PDF) Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. medRxiv World Health Organization Tracking SARS-CoV-2 variants Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Quantification of SARS-CoV-2 neutralizing antibody by a pseudotyped virus-based assay Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines Serum neutralizing activity elicited by mRNA-1273 vaccine -preliminary report Antibody evasion by the Brazilian P.1 strain of SARS-CoV-2 Infection and vaccineinduced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 Variants Membrane fusion and immune evasion by the spike protein of SARS-CoV-2 Delta variant Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study Vaccine-induced humoral and cellular immunity against SARS-CoV-2 at 6 months post BNT162b2 vaccination mRNA vaccine-elicited SARS-CoV-2-specific T cells persist at 6 months and recognize the delta variant Protection of BNT162b2 vaccine booster against Covid-19 in Israel 2021) SARS-CoV-2 neutralization with BNT162b2 vaccine dose 3 Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant Covid-19: where are we on vaccines and variants? Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State. medRxiv European Centre for Disease Prevention and Control SARS-CoV-2 variants of concern as of 18 Persistence and evolution of SARS-CoV-2 in an immunocompromised host Persistent SARS-CoV-2 infection and increasing viral variants in children and young adults with impaired humoral immunity. medRxiv Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England Covid-19: The E484K mutation and the risks it poses Antibody-dependent cellular phagocytosis in antiviral immune responses Chapter 1 -Antibodydependent cellular cytotoxicity (ADCC) First patients receive Moderna's modified COVID-19 vaccine candidates Vaccine hesitancy: the next challenge in the fight against COVID-19 2020) Developing Covid-19 vaccines at pandemic speed SARS-CoV-2 vaccines in development Measuring the impact of COVID-19 vaccine misinformation on vaccination intent in the UK and USA Why does drug resistance readily evolve but vaccine resistance does not? Monitor for COVID-19 vaccine resistance evolution during clinical trials Why the evolution of vaccine resistance is less of a concern than the evolution of drug resistance Full vaccination against COVID-19 suppresses SARS-CoV-2 delta variant and spike gene mutation frequencies and generates purifying selection pressure The ethics of COVID-19 immunity-based licenses The logic of China's vaccine diplomacy Economic effects of coronavirus outbreak (COVID-19) on the world economy Draft landscape and tracker of COVID-19 candidate vaccines The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity COVID-19 vaccinations: the unknowns, challenges, and hopes